Loading stock data…
FIGS
$14.29-0.25 (-1.72%)
Market OpenUpdated 1:24 PM EDT
FIGS, Inc., together with its subsidiary, FIGS Canada, Inc., operates as a direct-to-consumer healthcare apparel and lifestyle company in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
FIGS, Inc. in the Consumer Cyclical sector is trading at $14.29. The stock is currently 18% below its 52-week high of $17.48, remaining 36.4% above its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why FIGS maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
AMZNTSLAHD
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.29
Potential Downside
78.4%
Whystock Fair Value$3.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$17.75+24.2%
Range$14.00 – $22.00
Fundamentals
FIGS, Inc., together with its subsidiary, FIGS Canada, Inc., operates as a direct-to-consumer healthcare apparel and lifestyle company in the United States and internationally. The company designs and sells scrubwear and non-scrubwear offerings, such...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
84.84
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.64%
Volume
Today's trading volume
1.98M
Recent News
What FIGS (FIGS)'s Slowing Growth And Insider Share Sale Plans Mean For Shareholders
Recently, commentary on FIGS highlighted that the healthcare apparel company has delivered relatively modest multi-year revenue growth, shrinking earnings per share and an outlook for flat free cash flow margins, suggesting it is losing ground to competitors. At the same time, a Form 144 filing revealed insider Sarah Oughtred plans to sell shares acquired through vested equity awards, a move that does not dilute existing shareholders but may focus investors on the company’s current operating...
Wall Street Analysts See a 27.06% Upside in Figs (FIGS): Can the Stock Really Move This High?
The consensus price target hints at a 27.1% upside potential for Figs (FIGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
3 Consumer Stocks That Concern Us
Consumer discretionary businesses are levered to the highs and lows of economic cycles. Thankfully for the industry, demand trends seem to be healthy as discretionary stocks have gained 7.5% over the past six months. This performance has nearly mirrored the S&P 500.
2 Russell 2000 Stocks Worth Your Attention and 1 We Question
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Builders FirstSource's Q1 Earnings Lag Estimates, Sales Beat
BLDR Q1 EPS misses estimates as sales fall 10%. Sales, however, beat forecasts. The new 2026 outlook turns cautious while buybacks expand.